Hormonal
Intensive glycemic control (target HbA1c < 6%) significantly reduces the development of diabetic peripheral neuropathy (DPN) in patients with Type 1 Diabetes Mellitus (T1DM), but this benefit is not observed in patients with Type 2 Diabetes Mellitus (T2DM).
If you have Type 1 Diabetes, aiming for an HbA1c below 6% is the most effective way to prevent nerve damage. However, if you have Type 2 Diabetes, this aggressive target is not recommended due to lack of neuropathy benefit and increased mortality risk; standard control (7.0-7.9%) is advised instead.
Intensive glucose control achieved a significant reduction in the development of DPN in TIDM patients, and lifestyle modifications and exercise achieved it moderately in TIIDM patients.
Why this rating
Based on a systematic review of 11 studies including RCTs and cohort studies with over 23,000 participants, though quality varies.
Source
Prevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review
Lidia Carvajal-Moreno et al. · Journal of Clinical Medicine · 2022
DOI 10.3390/jcm11061723
More from this paper
- Moderate-intensity aerobic exercise and lifestyle modifications moderately prevent or improve diabetic peripheral neuropathy in patients with Type 2 Diabetes Mellitus (T2DM).Moderate
- Intensive lifestyle intervention (weight loss, reduced caloric intake, increased physical activity) does not significantly prevent diabetic peripheral neuropathy in patients with Type 2 Diabetes Mellitus (T2DM) and may have negative effects in some contexts.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →